Heino von Prondzynski
Heino von Prondzynski (*1949, Swiss/German) studied mathematics, geography, and history at the Westfälische Wilhelms University, Münster, Germany.
After graduation, Mr. von Prondzynski joined Bayer AG, where he held several positions within the company. Among other career accomplishments, Mr. von Prondzynski served as CEO of the diagnostics division of F. Hoffmann-La Roche Ltd., Basel, Switzerland and as member of the corporate executive committee of Roche. Currently, he is an independent consultant. Mr. von Prondzynski is an expert and business leader in the field of molecular diagnostics with an extensive professional network.
Mr. von Prondzynski was a Supervisory Board member of Epigenomics AG from May 2007 to March 2010, and has been a Supervisory Board member again since May 2012 (Chairman). He is an independent member (within the meaning of the German Corporate Governance Code). Mr. von Prondzynski’s current appointment ends in 2024.
Mr. von Prondzynski is not a member of other legally required supervisory boards. He is a member of comparable control committees of the following commercial enterprises: Quotient Ltd., Jersey, United Kingdom, and The Binding Site Group, Birmingham, United Kingdom.